Extract

The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.

Inclusion criteria

• Angioplasty, Transluminal, Percutaneous Coronary

Country

• Belgium
• Canada
• Czech Republic
• France
• Germany
• Netherlands
• Slovakia
• South Africa
• Spain
• United States

Links

• nct
• ictrp